

WEST**Freeform Search**

Database:

☐ US Patents Full-Text Database
☐ US Pre-Grant Publication Full-Text Database
☐ JPO Abstracts Database
☐ EPO Abstracts Database
☐ Derwent World Patents Index
☐ IBM Technical Disclosure Bulletins

L6 and replicon\$

Term:

Display: 100 Documents in Display Format: - Starting with Number 1Generate: ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show 8 Numbers

Edit 8 Numbers

Preferences

Cases

Search HistoryDATE: Wednesday, January 29, 2003 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L8</u>	L7 and Kunjin	0	<u>L8</u>
<u>L7</u>	L6 and replicon\$	7	<u>L7</u>
<u>L6</u>	flavivir\$ near10 vector\$	51	<u>L6</u>
<u>L5</u>	KUN near10 vector\$	1	<u>L5</u>
<u>L4</u>	Kunjin near10 vector\$	0	<u>L4</u>
<u>L3</u>	Kinjin near10 vector\$	0	<u>L3</u>
<u>L2</u>	L1 and expression near5 vector\$	29	<u>L2</u>
<u>L1</u>	Kunjin near5 (virus or viral or viruses)	47	<u>L1</u>

END OF SEARCH HISTORY

Generate Collection

Print

Search Results - Record(s) 1 through 51 of 51 returned.

1. 20030013195 . 21 Feb 02. 16 Jan 03. Virus envelope vector for gene transfer. Kaneda, Yasufumi. 435/456; 514/44 A61K048/00 C12N015/86.
2. 20030008282 . 06 Jun 01. 09 Jan 03. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening. Capon, Daniel J., et al. 435/6; 435/320.1 435/5 C12Q001/68 C12Q001/70 C12N015/869.
3. 20020198509 . 01 Jul 02. 26 Dec 02. Intradermal delivery of vaccines and gene therapeutic agents via microcannula. Mikszta, John A., et al. 604/500; 604/46 A61M031/00.
4. 20020164349 . 04 Oct 01. 07 Nov 02. Compositions and methods of using capsid protein from Flaviviruses and Pestiviruses. Weiner, David B., et al. 424/186.1; 435/5 530/350 530/826 536/23.72 C07K001/00 A61K039/12 C07H021/04 C12Q001/70 C07K017/00 C07K014/00.
5. 20020141975 . 16 Nov 01. 03 Oct 02. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines. Olmsted, Robert, et al. 424/93.2; 424/186.1 424/188.1 530/350 530/826 536/23.72 A61K048/00 A61K039/21 A61K039/12 C07H021/04 A01N063/00 C07K001/00 C07K014/00 C07K017/00.
6. 20020106379 . 12 Sep 01. 08 Aug 02. Membrane virus host range mutations and their uses as vaccine substrates. Hernandez, Racquel, et al. 424/188.1; 424/186.1 424/218.1 435/320.1 435/69.1 536/24.33 C12P021/06 A61K039/21 C12N015/00 C12N015/63 C12N015/74 A61K039/12 A61K039/193 C12N015/09 C12N015/70 C07H021/04.
7. 20020098199 . 09 Mar 01. 25 Jul 02. Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences. Van Nest, Gary, et al. 424/189.1; 514/44 A61K048/00 A61K039/29.
8. 20020034732 . 30 Jul 98. 21 Mar 02. COMPOSITIONS AND METHODS FOR DETERMINING ANTI-VIRAL DRUG SUSCEPTIBILITY AND RESISTANCE AND ANTI-VIRAL DRUG SCREENING. CAPON, DANIEL J., et al. 435/5; 435/252.3 435/32 435/320.1 435/6 C12Q001/70 C12Q001/68 C12Q001/18 C12P013/14 C12N001/20 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.
9. 6497884 . 03 Mar 00; 24 Dec 02. Chimeric vaccine against tick-borne encephalitis virus. Pletnev, Alexander, et al. 424/218.1; 424/199.1 424/93.1 424/93.2 435/235.1 435/236 435/320.1 435/69.3 536/23.72. A61K039/12 A01N063/00 C12N015/00 C12P021/06.
10. 6432411 . 13 Jul 99; 13 Aug 02. Recombinant envelope vaccine against flavivirus infection. Ivy, John, et al. 424/218.1; 424/186.1 424/279.1 424/283.1. A61K039/12.
11. 6416763 . 28 Aug 98; 09 Jul 02. Recombinant nonstructural protein subunit vaccine against flaviviral infection. McDonell, Michael, et al. 424/218.1; 424/186.1 424/202.1 435/5 435/69.1 435/69.3. A61K039/12.
12. 6309650 . 15 Jun 00; 30 Oct 01. Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine. Kim; Hyun Su, et al. 424/218.1; 424/184.1 435/235.1 435/236 435/237 435/245. A61K039/12.

13. 6306401 . 18 Sep 98; 23 Oct 01. Genetically-engineered sindbis virus with modified E2 Glycoprotein and altered host-range phenotype. Brown; Dennis T., et al. 424/218.1; 435/320.1. A61K039/12.
14. 6242187 . 10 Aug 99; 05 Jun 01. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening. Capon; Daniel J., et al. 435/6; 435/320.1 435/369 435/370. C12Q001/68.
15. 6207439 . 25 Mar 97; 27 Mar 01. Purification of Japanese encephalitis virus. Liao; Ming-Yi, et al. 435/239; 424/218.1 435/235.1 435/236. C12N007/02 C12N007/04 C12N007/00.
16. 6207426 . 16 Feb 99; 27 Mar 01. Conditionally replicating viral vectors and their use. Dropulic; Boro, et al. 435/91.41; 435/320.1 435/91.4. C12N015/63 C12N015/86.
17. 6165477 . 20 Aug 97; 26 Dec 00. Subunit immunogenic composition against dengue infection. Ivy; John, et al. 424/218.1; 424/184.1 424/186.1 435/69.3 435/70.1. A61K039/193.
18. 6156888 . 03 Jun 99; 05 Dec 00. Hybrid proteins with modified activity. Voorberg; Johannes J., 536/23.4; 536/23.1 536/23.5. C07H021/02 C07H021/04 A01N043/04.
19. 6156495 . 19 Apr 96; 05 Dec 00. Hepatitis GB virus recombinant proteins and uses thereof. Pilot-Matias; Tami J., et al. 435/5; 435/320.1 530/350 530/826. C12Q001/70 C12N015/00.
20. 6136561 . 25 Sep 97; 24 Oct 00. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems. Ivy; John, et al. 435/69.3; 424/218.1 435/69.7 435/69.8. C12N015/09.
21. 6130203 . 03 Feb 99; 10 Oct 00. Hybrid proteins with modified activity. Voorberg; Johannes J., 514/12; 514/2 514/834 530/383 930/100. A61K038/00 A61K035/14 A01N037/18.
22. 6117640 . 02 May 95; 12 Sep 00. Recombinant vaccine made in E. coli against dengue virus. Srivastava; Ashok Kumar, et al. 435/7.1; 424/186.1 424/218.1 435/69.1 435/7.9 435/7.92 435/975 436/536 530/350 536/23.4 536/23.72. A61K039/12 C07H021/04 C07K014/18.
23. 6074865 . 20 Jul 95; 13 Jun 00. Recombinant dengue virus DNA fragment. Kelly; Eileen P., et al. 530/395; 435/235.1 435/320.1 435/325 536/23.1. C07H021/04 C12N015/85 C12N007/00 C12N015/00.
24. 6051418 . 03 Feb 99; 18 Apr 00. Hybrid proteins with modified activity. Voorberg; Johannes J., 435/252.3; 435/252.33 435/325 435/366 435/69.6 530/324 530/350 530/383 536/23.5. C12N001/20 C12P021/04 A61K035/14 C07H021/04.
25. 5981172 . 06 Apr 95; 09 Nov 99. Non-A, non-B, non-C, non-D, non-E Hepatitis reagents and methods for their use. Simons; John N., et al. 435/5; 435/6 536/23.1 536/24.3. C12Q001/70 C12Q001/68 C07H021/02 C07H021/04.
26. 5980899 . 10 Jun 92; 09 Nov 99. Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells. Berzofsky; Jay A., et al. 424/185.1; 424/186.1 424/189.1 424/204.1 424/228.1 530/300 530/324 530/325 530/326 530/327 530/328. A61K039/00 A61K039/12 A61K039/29 C07K002/00.
27. 5910481 . 13 Nov 95; 08 Jun 99. Hybrid proteins with modified activity. Voorberg; Johannes

J.. 514/12; 435/69.1 435/69.6 435/69.7 514/8 514/834 530/350 530/383 930/100. A61K038/00
A61K035/14 C12P021/04 C12P021/06.

└ 28. 5869292 . 25 Jun 97; 09 Feb 99. Hybrid proteins with modified activity. Voorberg; Johannes
J.. 435/69.6; 435/69.1 435/69.7 530/324 530/350 530/383 536/23.5. C12P021/04 C12P021/06
A61K035/14 A61K038/00.

└ 29. 5843450 . 07 Jun 95; 01 Dec 98. Hepatitis GB Virus synthetic peptides and uses thereof.
Dawson; George J., et al. 424/189.1; 435/5 436/518 436/820 530/324 530/328 530/403. A61K039/12
G01N033/576.

└ 30. 5744141 . 07 Jun 95; 28 Apr 98. Flavivirus recombinant poxvirus immunological
composition. Paoletti; Enzo, et al. 424/199.1; 424/184.1 424/186.1 424/204.1 424/210.1 424/218.1
424/232.1 435/235.1 435/320.1 435/70.1 435/89. A61K039/285 A61K039/295 C07K014/18
C12N007/01.

└ 31. 5744140 . 07 Apr 94; 28 Apr 98. Flavivirus recombinant poxvirus vaccine. Paoletti; Enzo, et
al. 424/199.1; 424/186.1 424/218.1 424/232.1 435/235.1 435/320.1. A61K039/275 A61K039/295
C12N007/01.

└ 32. 5736148 . 11 May 95; 07 Apr 98. Infectious Japanese encephalitis virus cDNA clones that
produce highly attenuated recombinant Japanese encephalitis virus, and vaccines thereof. Sumiyoshi;
Hideo, et al. 424/218.1; 435/236. A61K039/12 C12N007/04.

└ 33. 5514375 . 13 Jun 91; 07 May 96. Flavivirus recombinant poxvirus vaccine. Paoletti; Enzo, et
al. 424/199.1; 424/184.1 424/202.1 424/204.1 424/205.1 424/218.1 424/232.1 435/235.1 435/320.1
435/69.3 514/2 530/350 530/826 536/23.72. A61K039/285 A61K039/295 C07K014/18 C12N007/01.

└ 34. 5494671 . 20 Aug 91; 27 Feb 96. C-terminally truncated dengue and Japanese encephalitis
virus envelope proteins. Lai; Ching-Jun, et al. 424/218.1; 424/185.1 424/186.1 424/199.1 424/202.1
424/204.1 435/69.3 514/2 530/350 530/826 536/23.72. A61K039/12 A61K039/295 C07K014/18.

└ 35. 5486473 . 09 Feb 94; 23 Jan 96. A DNA coding for a Flavivirus antigen. Fujita; Hiroyuki, et
al. 435/252.33; 435/320.1 536/23.72. C12N005/10 C12N001/21 C12N015/40 C12N015/70.

└ 36. 4810492 . 19 Nov 86; 07 Mar 89. Flavivirus antigen. Fujita; Hiroyuki, et al. 424/186.1;
424/192.1 424/218.1 530/350 536/23.72 930/220. A61K037/02 C07K013/00.

└ 37. 4447537 . 22 Jan 81; 08 May 84. Tick cell lines. Yunker; Conrad E., et al. 435/235.1;
424/204.1 424/215.1 424/218.1 424/224.1 424/234.1 435/243 435/325 435/948. A61K039/00
A61K039/12.

└ 38. GB 2372991 A . 09 Mar 01. 11 Sep 02. Flavivirus expression vector. BONALDO, MIRNA
C, et al. C12N015/86; A61P037/02 C12N015/67.

└ 39. WO 9928487 A1 . 30 Nov 98. 10 Jun 99. FLAVIVIRUS EXPRESSION AND DELIVERY
SYSTEM. WESTAWAY, EDWIN G, et al. C12N015/86;.

└ 40. EP 869184 A2 . 06 Jul 95. 07 Oct 98. Vaccin for immunisation against TBE viral infections
and method or its preparation. HEINZ, FRANZ XAVER PROF DR, et al. C12N015/86; C12N015/40
A61K048/00.

└ 41. WO 200281741 A2 FR 2823224 A1 . Identifying stimulators of oligoadenylate synthase

family genes, useful as antiviral agents against Flavivirus, also mutated genes responsible for sensitivity to virus. BONHOMME, F, et al. A01K067/027 A61K031/708 A61K038/00 A61K038/45 A61K048/00 A61P031/14 C12N005/06 C12N005/10 C12N009/10 C12N015/12 C12Q001/02 C12Q001/68.

42. WO 200274963 A1 . New mutant replicon-defective flavivirus having a genome with a 3' stem-loop structure chimeric substitution useful as vaccine for treating flavivirus-induced infection e.g. dengue fever, dengue hemorrhagic fever/shock syndrome. MARKOFF, L, et al. A01K067/033 A61K039/12 A61K048/00 C12N007/01 C12N015/40.

43. GB 2372991 A WO 200272835 A1 . Novel Flavivirus vector useful for expressing heterologous antigens, comprises foreign gene sequences inserted at sites in the level of its envelope protein. BONALDO, M C, et al. A61K039/00 A61K039/015 A61P037/02 C12N015/40 C12N015/67 C12N015/86.

44. US 20020034732 A1 . Determining the drug susceptibility of hepatitis C virus or human cytomegalovirus comprises using a resistance test vector containing a patient-derived segment having a viral gene and an indicator gene. CAPON, D J, et al. C12N001/20 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C12P013/14 C12Q001/18 C12Q001/68 C12Q001/70.

45. EP 1250421 A1 WO 200153467 A1 AU 200129656 A BR 200107703 A . Recombinant flavivirus useful for reducing the number of tumor cells in a host comprises an exogenous nucleic acid encoding a polypeptide proteolytically processed after expression in the vector resulting in its release. ANDINO-PAVLOVSKY, R, et al. A61K039/00 A61K048/00 C12N005/10 C12N007/01 C12N015/62 C12N015/86.

46. US 20020172937 A1 WO 200049413 A2 AU 200034946 A . Analyzing an arthropod sample for the presence of analytes associated with the pathogen causing malaria, specifically Plasmodium, useful in detecting disease vectors and arthropod-carried pathogens, comprises a dipstick assay. DAVE, K, et al. A01N043/04 A61K031/70 C12P019/34 C12P021/06 C12Q001/68 C12Q001/70 G01N033/569.

47. WO 200014245 A1 AU 9926610 A EP 1108036 A1 . A mutant replication-defective flavivirus (I) having a genome with a 3' stem-loop structure substitution, useful as a vaccine for protecting against flavivirus infection or disease. MARKOFF, L, et al. A01K067/033 A61K039/12 A61K048/00 C12N007/01 C12N015/40.

48. WO 9928487 A1 JP 2002500003 W AU 9915517 A EP 1034290 A1 AU 733155 B . Flavivirus expression and delivery system. KHRAMYKH, A, et al. C12N015/09 C12N015/86 C12N015/09 C12R001/92.

49. EP 869184 A2 ES 2165109 T3 EP 869184 B1 DE 59509667 G . Vaccine against flavivirus infection, especially tick-borne encephalitis - comprises full-length native protein E and prM/M coding sequences. ALLISON, S, et al. A61K039/12 A61K048/00 C07K014/18 C12N015/40 C12N015/85 C12N015/86.

50. WO 9823754 A1 MX 9904908 A1 AU 9853973 A CN 1258317 A BR 9713540 A . New genes coding for dengue virus type 2 and 4 envelope proteins - and Pichia pastoris expression systems, useful for recombinant production of the proteins for vaccines and diagnosis. ALVAREZ ACOSTA, A, et al. A61K039/12 C07K014/18 C12N001/21 C12N007/04 C12N015/40.

51. US N7747785 N WO 9203161 A AU 9187625 A WO 9303763 A1 AU 9224972 A US 5494671 A . New recombinant C-terminal truncated flavivirus E proteins - are more immunogenic than full length proteins, for use in safe and effective vaccines. BRAY, M, et al. A61K039/12 A61K039/295 C07K003/00 C07K014/18 C07K015/12 C12N000/01 C12N001/20 C12N007/00 C12N015/00.

[Generate Collection](#)[Print](#)**Terms****Documents**

flavivir\$ near10 vector\$

51

[Previous Page](#)[Next Page](#)